P3-041: Elevated serum copper level in Alzheimer's disease

2012 ◽  
Vol 8 (4S_Part_13) ◽  
pp. P469-P470
Author(s):  
Dong Woo Lee ◽  
Jun-Hyun Park
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Elevated Serum ◽  
Serum Copper ◽  
Copper Level ◽  
Serum Copper Level

scholarly journals Utility of Serum Copper Level Estimation in Patients Suffering from Alzheimer’s Disease

2017 ◽  
Vol 33 (2) ◽  
pp. 96-102
Author(s):  
Dewan Mushfiqur Rahman ◽  
SK Mahbub Alam ◽  
Shamshad B Quraishi ◽  
Imran Sarker ◽  
Md Rafiqul Islam ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Serum Copper ◽  
High Serum ◽  
Total Serum ◽  
Copper Level ◽  
Control Group ◽  
Serum Copper Level ◽  
Control Groups ◽  
And Control

Background: Alzheimer’s disease is the most common cause of dementia. Metals such as zinc , copper, iron are likely involved in the neurodegeneration of Alzheimer’s disease . Copper can catalyze a flux of reactive oxygen species that can damage functional and structural macromolecules in brain. Most studies found association of high serum copper level with Alzheimer’s disease but also some studies did not. Methods: Total 48 patients of Alzheimer’s disease who were diagnosed according to NIA-AA ( National institute of Aging – Alzheimer’s Association) recommendation ( revised NINCDS-ADRDA) criteria were taken as study population purposively and 42 age and sex matched control were selected. Fasting serum copper level were done for both groups. Comparison of serum copper level of Alzheimer’s patients with that of the control group were done to see association. Results : A total of 28 male and 20 female with mean age of 66.20 ± 9.42 (mean±SD) years, 22 male and 20 female with mean age of 63.54 ± 9.74 (mean±SD) years constituted as case and control groups, respectively. The mean of serum copper in case and control groups were 0.95 ± 0.37 versus 0.92 ± 0.25 mg/L (P > 0.05). The present study found that serum copper levels are non-significantly higher in patients with AD than control group, however it did not show a significant relationship with severity of dementia. Conclusion: So our suggestion was to perform a study work including total serum copper level , serum ceruloplasmin level and free serum copper level comparing between a large Alzheimer’s Disease patients group and age , sex matched apparently healthy control group to understand the copper dyshomeostasis in Alzheimer’ Disease. Bangladesh Journal of Neuroscience 2017; Vol. 33 (2): 96-102

Elevated serum copper and ceruloplasmin levels in Alzheimer's disease

2013 ◽  
Vol 6 (1) ◽  
pp. 38-45 ◽  
Author(s):  
Jun-Hyun Park ◽  
Dong-Woo Lee ◽  
Kyung Soo Park
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Elevated Serum ◽  
Serum Copper

Serum Copper Level and Polycystic Ovarian Syndrome: A Meta-Analysis

2021 ◽  
pp. 1-8
Author(s):  
Qingtao Jiang ◽  
Feng Zhang ◽  
Lei Han ◽  
Baoli Zhu ◽  
Xin Liu
Keyword(s):  
Large Scale ◽  
Polycystic Ovarian Syndrome ◽  
Meta Analysis ◽  
Serum Copper ◽  
Copper Level ◽  
Serum Copper Level ◽  
Copper Status ◽  
Plasma Copper ◽  
Mean Differences ◽  
Ovarian Syndrome

<b><i>Introduction:</i></b> The association of serum copper with polycystic ovarian syndrome (PCOS) has been studied for years, but no definite conclusion is drawn. Therefore, we conducted a meta-analysis to investigate serum copper concentrations in PCOS subjects compared with healthy controls. <b><i>Methods:</i></b> Electronic search was performed in PubMed, Google Scholar, and Scopus up to June 30, 2020, without any restriction. Standardized mean differences (SMDs) with corresponding 95% CIs in serum copper levels were employed with random-effects model. <i>I</i><sup>2</sup> was applied to evaluate heterogeneity among studies. <b><i>Results:</i></b> Nine studies, measuring plasma copper levels in 1,168 PCOS patients and 1,106 controls, were included. Pooled effect size suggested serum copper level was significantly higher in women with PCOS (SMD = 0.51 μg/mL, 95% CI = [0.30, 0.72], <i>p</i> &#x3c; 0.0001). The overall heterogeneity was not connected with subgroups of the country, but derived from the opposite result of 1 study. <b><i>Conclusion:</i></b> Our research generally indicated circulating copper level in PCOS sufferers was significantly higher than normal controls. Large-scale studies are still needed to elucidate the clear relation between copper status and etiology of PCOS.

Oxidative Stress Markers and Metal Ions are Correlated With Cognitive Function in Alzheimer’s Disease

2017 ◽  
Vol 32 (6) ◽  
pp. 353-359 ◽  
Author(s):  
Zhengping Pu ◽  
Wenjie Xu ◽  
Yong Lin ◽  
Jincai He ◽  
Manli Huang
Keyword(s):  
Oxidative Stress ◽  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Metal Ions ◽  
Serum Levels ◽  
Zinc Level ◽  
Copper Level ◽  
Iron Level ◽  
Oxidative Stress Markers ◽  
Stress Markers

We investigated oxidative stress markers and metal ions in patients with Alzheimer’s disease (AD). The serum levels of ceruloplasmin (CER), C-reactive protein (CRP), uric acid (UA), homocysteine (Hcy), copper, iron, and zinc were determined in 125 patients with AD (mild, n = 2 8; moderate, n = 42; and severe, n = 55) and 40 healthy control (HC) participants. Compared to HC, CER and UA levels were significantly lower in moderate and severe AD groups, whereas CRP and Hcy levels were significantly higher in the severe AD group. Copper level was significantly higher in moderate and severe AD groups than the other groups. Compared to HC, iron level was significantly higher in patients with AD, whereas zinc level was significantly lower in patients with AD. In patients with AD, the severity of cognitive impairment was positively correlated with CER, UA, and zinc levels, whereas it was negatively correlated with copper level. Taken together, our findings provide a novel approach to assess AD progression.

scholarly journals Serum Copper with Coronary Artery Disease in Male and its Relation with Lipid Profile

1970 ◽  
pp. 7-9
Author(s):  
Sifat Jubaira ◽  
Forhadul Haque Mollah ◽  
Tahrim Mehdi ◽  
M Iqbal Arslan
Keyword(s):  
Myocardial Infarction ◽  
Coronary Artery Disease ◽  
Acute Myocardial Infarction ◽  
Coronary Artery ◽  
Lipid Profile ◽  
Density Lipoprotein ◽  
Serum Copper ◽  
Copper Level ◽  
Serum Copper Level ◽  
Artery Disease

The study was designed to explore serum copper as a risk factor for coronary artery disease (CAD). In this case-control study 30 healthy controls and 60 diagnosed cases of acute myocardial infarction (AMI) were enrolled. Serum copper concentration and serum lipid profile were measured in all study subjects. Serum copper level was significantly higher in AMI as compared to controls. The concentrations of serum TC, TG, LDL-C level were found to be significantly higher in cases as compared to controls. The concentration serum HDL-C was found to be significantly lower in cases as compared to controls. CAD leads to raised serum copper level and it has positive correlation with TC, TG and LDL-C but negative correlation with HDL-C in males.Keywords: Coronary artery disease; serum copper; acute myocardial infarction; total cholesterol; triglyceride; low density lipoprotein cholesterol. DOI: 10.3329/bjpp.v24i1.5730Bangladesh J Physiol Pharmacol 2008; 24(1&2) : 7-9

scholarly journals Serum VEGF Predicts Clinical Improvement Induced by Cerebrolysin Plus Donepezil in Patients With Advanced Alzheimer’s Disease

2020 ◽  
Vol 23 (9) ◽  
pp. 581-586
Author(s):  
X Anton Alvarez ◽  
Irene Alvarez ◽  
Antia Martinez ◽  
Iria Romero ◽  
Concha Benito ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Controlled Trial ◽  
Combined Therapy ◽  
Elevated Serum ◽  
Vascular Endothelial ◽  
Functional Responses ◽  
Randomized Controlled ◽  
Trial Treatment ◽  
Endothelial Growth Factor

Abstract Serum vascular endothelial growth factor (VEGF) increases with Alzheimer’s disease (AD) severity and may prevent cognitive decline. However, information on the influence of AD drug therapy on circulating VEGF is limited. This study assessed changes in serum VEGF levels and its association with clinical and functional responses in mild to moderate AD patients who were treated with Cerebrolysin, donepezil, or the combined therapy in a randomized, controlled trial. Treatment with Cerebrolysin plus donepezil reduced elevated serum VEGF levels and improved functioning and cognition significantly compared with donepezil alone in patients with advanced AD, and treatment differences were more pronounced in patients with higher VEGF levels. Our results indicate that the combined therapy reversed the increase of serum VEGF in advanced AD, which was associated with cognitive and functional responses, particularly in patients with high baseline VEGF.

Sign in / Sign up

Export Citation Format

Share Document